Experimental radioimmunotherapy1
References (165)
- et al.
A high-affinity human antibody that targets tumoral blood vessels
Blood
(1999) - et al.
Studies concerning the effect of external irradiation on localization of radiolabeled monoclonal antibody B72.3 to human colon carcinoma xenografts
Int J Radiat Oncol Biol Phys
(1989) - et al.
A comparison of 131I-labeled monoclonal antibody 17-1A treatment to external beam irradiation on the growth of LS174T human colon carcinoma xenografts
Int J Radiat Oncol Biol Phys
(1990) - et al.
Comparison of 131I- and 90Y-labeled monoclonal antibody 17-1A for treatment of human colon cancer xenografts
Int J Radiat Oncol Biol Phys
(1993) - et al.
The hypoxic cytotoxin SR 4233 increases the effectiveness of radioimmunotherapy in mice with human non-Hodgkin's lymphoma xenografts
Int J Radiat Oncol Biol Phys
(1994) - et al.
Addition of cisplatin improves efficacy of 131I-labeled monoclonal antibody 323/A3 in experimental human ovarian cancer
Int J Radiat Oncol Biol Phys
(1997) - et al.
The importance of antibody-specificity in determining successful radioimmunotherapy of B-cell lymphoma
Blood
(1999) Lymphokine receptors: A target for immunotherapy of lymphomas
Ann Oncol
(1994)- et al.
Experimental radioimmunotherapy
Med Phys
(1993) Experimental radioimmunotherapy: A brief overview
Cancer
(1994)
Overview of studies on experimental radioimmunotherapy
Cancer Res
(1995)
Experimental radioimmunotherapy and methods to increase therapeutic efficacy
Modeling analysis of the global and microscopic distribution of immunoglobulin G, F(ab')2, and Fab in tumors
Cancer Res
(1989)
Vascular and interstitial barriers to delivery of therapeutic agents in tumors
Cancer Metastasis Rev
(1990)
An analysis of monoclonal antibody distribution in microscopic tumor nodules: Consequences of a “binding site barrier”
Cancer Res
(1991)
Pharmacokinetic analysis of the perivascular distribution of bifunctional antibodies and haptens: Comparison with experimental data
Cancer Res
(1992)
Reconciliation of tumor dose response to external beam radiotherapy versus radioimmunotherapy with 131iodine-labeled antibody for a colon cancer model
Cancer Res
(1995)
Implications of nonuniform tumor doses for radioimmunotherapy
J Nucl Med
(1999)
Radioimmunotherapy of micrometastases in lung with vascular targeted 213Bi
Br J Cancer
(1999)
Identification of endosialin, a cell surface glycoprotein of vascular endothelial cells in human cancer
Up-regulation of endoglin on vascular endothelial cells in human solid tumors: Implications for diagnosis and therapy
Clin Cancer Res
(1995)
A murine model for antibody-directed targeting of vascular endothelial cells in solid tumors
Cancer Res
(1992)
Increased binding affinity and valence of recombinant antibody fragments lead to improved targeting of tumoral angiogenesis
Cancer Res
(1999)
Human monoclonal antibodies and engineered antibodies in the management of cancer
Semin Cancer Biol
(1990)
Generation of tumor cell-reactive human monoclonal antibodies using peripheral blood lymphocytes from actively immunized colorectal carcinoma patients
Cancer Res
(1985)
Reshaping human antibodies for therapy
Nature
(1988)
Improving monoclonal antibody pharmacokinetics via chemical modification
Q J Nucl Med
(1998)
Chemical modification to reduce renal uptake of disulfide-bonded variable region fragment of anti-Tac monoclonal antibody labeled with 99mTC
Bioconj Chem
(1999)
Cytotoxic effects of anti-CD5 radioimmunotoxins on human tumors in vitro and in a nude mouse model
Cancer Res
(1988)
Preclinical assessments of 90Y-labeled C110 anti-carcinoembryonic antigen immunotoxin: A therapeutic immunoconjugate for human colon cancer
Cancer Res
(1991)
Radiolabeled fusion toxin binding, cytotoxicity and localization to colon cancer cells induced to express IL-4 receptor
Iodine-131-labeled MAb F(ab')2 fragments are more efficient and less toxic than intact anti-CEA antibodies in radioimmunotherapy of large human colon carcinoma grafted in nude mice
J Nucl Med
(1990)
Successful radioimmunotherapy for lung, metastasis of human colonic cancer in nude mice
J Natl Cancer Inst
(1991)
Rapid tumor penetration of a single-chain Fv and comparison with other immunoglobulin forms
Cancer Res
(1992)
Experimental studies on the role of antibody fragments in cancer radioimmunotherapy: Influence of radiation dose and dose rate on toxicity and anti-tumor efficacy
Int J Cancer
(1998)
Characterization of scFv-Ig constructs generated from the anti-CD20 mAb 1F5 using linker peptides of varying lengths
J Immunol
(1999)
Pretargeting: General principles; October 10–12, 1996
Cancer
(1997)
Clinical application of the avidin-biotin system for tumor targeting
Delivery of therapeutic doses of radioiodine using bispecific antibody-targeted bivalent haptens
J Nucl Med
(1998)
Pretargeting with the affinity enhancement system for radioimmunotherapy
Cancer Biother Radiopharm
(1999)
Three-step radioimmunotherapy with yttrium-90 biotin: Dosimetry and pharmacokinetics in cancer patients
Eur J Nucl Med
(1999)
Phage libraryderived human anti-TETA and anti-DOTA ScFv for pretargeting RIT
Hybridoma
(1999)
Improving the tumor retention of radioiodinated antibody: Aryl carbohydrate adducts
Cancer Res
(1990)
Improved therapeutic efficacy of a monoclonal antibody radioiodinated using N-succinimidyl-3-(tri-n-butylstannyl)benzoate
Cancer Res
(1991)
Enhanced tumor specificity of 741F8-1 (sFv')2, an, anti-c-erbB-2 single-chain Fv dimer, mediated by stable radioiodine conjugation
J Nucl Med
(1995)
Radiochemistry of therapeutic radionuclides
Advantage of a residualizing iodine radiolabel for radioimmunotherapy of xenografts of human non-small-cell carcinoma of the lung
J Nucl Med
(1997)
Synthesis of N-[tris[2-[[N-(benzyloxy)amino]carbonyl]ethyl]methyl]succinamic acid, trisuccin: Hydroxamic acid derivatives as a new class of bifunctional chelating agents
Bioconj Chem
(1993)
Optimized conditions for chelation of yttrium-90-DOTA immunoconjugates
J Nucl Med
(1998)
Dosimetric aspects of radiolabeled antibodies for tumor therapy
J Nucl Med
(1986)
Cited by (29)
Targeted Radionuclide Therapy
2015, Clinical Radiation OncologyTargeted Radionuclide Therapy
2011, Clinical Radiation Oncology: Third EditionSystemic Targeted Radionuclide Therapy symposium introduction
2006, International Journal of Radiation Oncology Biology PhysicsTargeted radionuclide therapy for solid tumors: An overview
2006, International Journal of Radiation Oncology Biology PhysicsCitation Excerpt :Although combinations of RIT with PBSC permits delivery of several times more radionuclide/radiation dose, it diminishes the simplicity of RIT and increases the adverse events (15). The potential for CMRIT has been shown (59–65). Both agent type and timing of delivery are important determinants of the outcomes (66).
Tumour therapy with radionuclides: Assessment of progress and problems
2003, Radiotherapy and OncologyDifferentiation therapy of human cancer: Basic science and clinical applications
2001, Pharmacology and Therapeutics
- 1
Supported by NIH grants R01 CA62550, CA73636, and CA78505, and DOE grants DE-FG02-93ER6154 and DE-FG02-96ER62181.
Copyright © 2000 Published by Elsevier Inc.